Last reviewed · How we verify
Prevnar 20 vaccine
Prevnar 20 is a pneumococcal conjugate vaccine that stimulates the immune system to produce antibodies against 20 serotypes of Streptococcus pneumoniae.
Prevnar 20 is a pneumococcal conjugate vaccine that stimulates the immune system to produce antibodies against 20 serotypes of Streptococcus pneumoniae. Used for Prevention of invasive pneumococcal disease in adults aged 18 years and older, Prevention of pneumococcal pneumonia in adults aged 18 years and older.
At a glance
| Generic name | Prevnar 20 vaccine |
|---|---|
| Also known as | Prevnar20™, Prevnar20® |
| Sponsor | Sanofi |
| Drug class | Pneumococcal conjugate vaccine |
| Target | Streptococcus pneumoniae polysaccharide capsules (20 serotypes) |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
The vaccine contains polysaccharide capsules from 20 different serotypes of pneumococcus conjugated to a carrier protein, which enhances immunogenicity. This conjugation allows the vaccine to trigger both T-cell and B-cell responses, providing protection against invasive pneumococcal disease and pneumococcal pneumonia caused by these serotypes. The expanded serotype coverage (compared to earlier pneumococcal conjugate vaccines) aims to provide broader protection against circulating pneumococcal strains.
Approved indications
- Prevention of invasive pneumococcal disease in adults aged 18 years and older
- Prevention of pneumococcal pneumonia in adults aged 18 years and older
Common side effects
- Injection site pain
- Injection site erythema
- Injection site swelling
- Myalgia
- Fatigue
- Headache
- Fever
Key clinical trials
- Influence of Methotrexate Discontinuation on Immunogenicity After PCV-20 Vaccine in Patients ARDs (PHASE4)
- Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Prior Pneumococcal Vaccination (PHASE3)
- Dose-Ranging Study to Evaluate a 25-Valent Pneumococcal Conjugate Vaccine (PHASE2)
- Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Immunobridging to Adults 18-49 (PHASE3)
- A Study to Understand the Safety of the 20vPnC Vaccine in Healthy Chinese Adults, Children, and Infant (PHASE1)
- A Study to Learn About the Safety of PREVENAR 20 Vaccine in Infants Aged Between Two to Six Months
- A Study to Learn More About Prevenar 20 Once it is Out in the Korean Market
- A Clinical Study of the V116 Vaccine for Children and Teenagers (V116-013) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Prevnar 20 vaccine CI brief — competitive landscape report
- Prevnar 20 vaccine updates RSS · CI watch RSS
- Sanofi portfolio CI